Corporate Profile for C.R. Bard dated July 7.--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and information services See Information Systems. . These include Dow Jones Dow Jones the best known of several U.S. indexes of movements in price on Wall Street. [Am. Hist.: Payton, 202] See : Finance News/Retrieval, Bloomberg Financial Markets, Reuter Company Newsyear, Reuter Business Briefing, DataTimes, Nexis, Dialog, NewsNet, America OnLine See AOL. , CompuServe, Delphi, Individual's HeadsUp and First!, Desktop Data's NewsEdge, UMI UMI University Microfilms International UMI United States Minor Outlying Islands (ISO Country code) UMI University of Miami UMI Universal Management Infrastructure (IBM) Data Courier, NewsBank, Information Access Company and many others. -0- Published date: July 7, 1995 Company name: C.R. Bard
Address: 730 Central Ave.
Murray Hill, NJ 07974
Telephone No.: 908/277-8000 Chief Executive Officer: William H. Longfield Chief Financial Officer: William C. Bopp Investor Relations Contact: E.L. Parker Business number: 908/277-8059 Public Relations Contact: E.L. Parker Trading symbol: BCR Industry: Health Care Company description: C.R. Bard Inc. is a leading multinational developer, manufacturer and marketer of health care products. Bard holds strong positions in cardiovascular, urological and surgical products. The company markets its products worldwide to hospitals, individual health care professionals, extended care facilities and alternate site facilities, employing a combination of direct delivery and medical specialty medical specialty Any specialty that provides non-interventional Pt management, ie with drugs, or with minimum intervention–eg, balloon catheterization Examples Internal medicine–allergy and immunology, cardiology, gastroenterology, hematology/oncology, distributors. Bard was a pioneer in the development of single patient use medical products for standard hospital procedures. It continually expands its research toward the improvement of existing products and the development of new products which offer cost-effective, recognizable benefits to patients. The company employs approximately 8,650 people worldwide. Bard reported 1994 sales of $1.018 billion. Sales by product group are as follows: Cardiovascular sales which make up 36% of the total, amounted to $383.9 million and include angioplasty angioplasty (ăn`jēōplăs'tē), any surgical repair of a blood vessel, especially balloon angioplasty or percutaneous transluminal coronary angioplasty, a treatment of coronary artery disease. catheters, angiographic catheters, electrophsiology products as well as open-heart surgical products, including blood oxygenators. Urological sales totaled $292.8 million and account for 29 percent of total sales, consisting of a complete urological line of products including Foley catheters, trays, related urine collection systems and many specialty items. Surgical sales totaled $353.4 million and account for 35 percent of the total. These products include wound draining devices, implantable blood vessel blood vessel n. An elastic tubular channel, such as an artery, a vein, a sinus, or a capillary, through which the blood circulates. blood vessel(s), n the network of muscular tubes that carry blood. replacements, a full line of specialty access catheters and a variety of endoscopy endoscopy Examination of the body's interior through an instrument inserted into a natural opening or an incision, usually as an outpatient procedure. Endoscopes include the upper gastrointestinal endoscope (for the esophagus, stomach, and duodenum), the colonoscope (for the , suction and irrigation irrigation, in agriculture, artificial watering of the land. Although used chiefly in regions with annual rainfall of less than 20 in. (51 cm), it is also used in wetter areas to grow certain crops, e.g., rice. products. International sales (included in the figures above) amounted to $307.0 million in 1994 and represented 30 percent of total sales. Company spending on R&D was $69.8 million in 1994, up $3.5 million over 1993. CONTACT: C.R. Bard Inc. E.L. Parker, 908/277-8059 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion